Malignant hyperthermia susceptibility in three patients with malignant neuroleptic syndrome;Susceptibilidade à hipertermia maligna em três pacientes com síndrome maligna por neurolépticos

Arquivos de Neuro-Psiquiatria

Volumn 58, Issue 3 A, 2000, Pages 713-719

  Silva, Helga C A ^a   Bahia, Valéria S ^a   Oliveira, Rogério A A ^a   Marchiori, Paulo E ^a   Scaff, Milberto ^a   Tsanaclis, Ana Maria C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Malignant hyperthermia; Muscle disease; Neuroleptic malignant syndrome

Indexed keywords

CAFFEINE; DIAGNOSTIC AGENT; HALOTHANE;

ADULT; ARTICLE; CASE REPORT; CONTRACTURE; DISEASE PREDISPOSITION; FEMALE; HUMAN; MALE; MALIGNANT HYPERTHERMIA; NEUROLEPTIC MALIGNANT SYNDROME;

ADULT; CAFFEINE; CONTRACTURE; DISEASE SUSCEPTIBILITY; FEMALE; HALOTHANE; HUMANS; MALE; MALIGNANT HYPERTHERMIA; NEUROLEPTIC MALIGNANT SYNDROME;

EID: 0034266008     PISSN: 0004282X     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0004-282x2000000400018     Document Type: Article

References (35)

1. Kozak-Reiss G, Coursange F, Aubert M. Hyperthermies malignes. In Encyclopedic Medico-chirurgicale. Techniques Chirurgicales. Anesthésie - Reanimation Paris: Ed. Techniques, 1991:1-18.
2. Tein I, DiMauro S, Rowland LP. Myoglobinuria . In: Rowland LP, DiMauro S (eds). Handbook of clinical neurology, myopathies. Amsterdam Elsevier, 1992:553-574.
3. Lunardi J. Genetic investigation of a rare disease: malignant hyperthermia. In Tegazzin V, Pintore G, Vincenti E (eds). Anestesia e malatie neuromuscolari. Torino: Minerva Medica, 1998:140-143.
4. Loke J, MacLennan DH. Malignant hyperthermia and central core disease: disorders of Ca 2+ release channels. Am J Med 1998;104:470-486.
5. Hopkins PM, Halsall PJ, Ellis ER. Diagnosing malignant hyperthermia susceptibility. Anaesthesia 1994;49:373-375.
6. Loke JCP, MacLennan DH. Bayesian modeling of muscle biopsy contracture testing for malignant hyperthermia susceptibility. Anesthesiology 1998;88:589-600.
7. Ellis FR, Halsall PJ, Ording H, et al. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. Br J Anaesth 1984;56:1267-1269.
8. Bendahan D, Kozak-Ribbens G, Rodet L, Confort-Gouny S, Cozzone PJ. 31Phosphorus magnetic resonance spectroscopy characterization of muscular metabolic anomalies on patients with malignant hyperthermia. Anesthesiology 1998;88:96-107.
9. Bertorini TE. Myoglobinuria, malignant hyperthermia, neuroleptic malignant syndrome and serotonin syndrome. Neurol Clin 1997;15:649-671.
10. Granner MA, Wooten GF. Neuroleptic malignant syndrome or parkinsonism hyperpirexia syndrome. Semin Neurol 1991;11:228-235.
11. Heiman-Patterson T.D. Neuroleptic malignant syndrome and malignant hyperthermia. Med Clin N Am 1993;77:477-492.
12. Toru M, Matsuda O, Makiguchi K, Sugano K. Neuroleptic malignant syndrome-like state following a withdrawal of antiparkinsonian drugs. J Nerv Ment Dis 1981;169:324-327
13. Caroff S, Rosenberg H. Neuroleptic malignant syndrome and malignant hyperthermia. J Clin Psychopharmacol 1983;3:120-121.
14. Downey GP, Rosenberg M, Caroff S et al. Neuroleptic malignant syndrome. Am J Med 1984;77:338-340.
15. Krivosic-Horber R, Adnet P, Guevart E, Theunynck D, Lestavel P. Neuroleptic malignant syndrome and malignant hyperthermia. Br J Anaesth 1987;59:1554-1556.
16. Adachi H, Riku S, Fujishiro K, Kuru S. A case of Satoyoshi syndrome with symptons resembling neuroleptic malignant syndrome. Rinsho Shinkeigaku 1998;38:637-640.
17. Calore EE, Cavaliere MJ, Perez NM, Russo DH, Wakamatsu A, Razzouk D. Hyperthermic reaction to haloperidol with rigidity, associated to central core disease. Acta Neurol 1994;16:157-161.
18. Caroff SN, Rosenberg H, Fletcher JE, Heiman-Patterson TD, Mann SC. Malignant hyperthermia susceptibility in neuroleptic malignant syndrome. Anesthesiology 1987;67:20-25.
19. Kelly D, Brull SJ. Neuroleptic malignant syndrome and mivacurium: a safe alternative to succinylcholine? Can J Anaesth 1994;41:845-849.
20. May DC, Morris SW, Stewart RM, Fenton BJ, Gaffney FA. Neuroleptic malignant syndrome: response to dantrolene sodium. Ann Intern Med 1983;98:183-184.
21. Weinberg S, Twersky RS. Neuroleptic malignant syndrome. Anesth Analg 1983;62:848-850.
22. Acharya SRK, Rao ARG. The action of chlorpromazine on the skeletal muscle of frog. Curr Sci 1975;44:147-149.
23. 2+) in skeletal muscle. (Abstr). Can J Anaesth 1989;36:S147-148.
24. Hermesh H, Aizenberg D, Lapidot M, Munitz H. Risk of malignant hyperthermia among patients with neuroleptic malignant syndrome and their families. Am J Psychiatry 1988;145:1431-1434.
25. Miyatake R, Iwahashi K, Matsushita M, Nakamura K, Suwaki H. No association between the neuroleptic malignant syndrome and mutations in the RYR1 gene associated malignant hyperthermia. J Neurol Sci 1996;143:161-165.
26. Adnet P, Krivosic-Horber R, Reyford H, Leys D. Adamantidis M, Dupuis B. Le syndrome malin des neuroleptiques et l'hyperthermie maligne anesthésique ont-ils un mécanisme commun? Presse Med 1990;19:1460.
27. Adnet PJ, Krivosic-Horber RM, Adamantidis MM, et al. The association between the neuroleptic malignant syndrome and malignant hyperthermia. Acta Anaesthesiol Scand 1989;33:676-680.
28. Bello N, Adnet P, Saulnier F, et al. Absence de sensibilité à l'hyperthermie maligne peranesthésique chez 32 patients ayant développé un syndrome malin des neuroleptiques. Ann Fr Anesth Réanim 1994;13:663-668.
29. Mauritz W, Hackl W, Winkler M, Sporn P, Steinbereithner, K. Anesthesia in malignant hyperthermia susceptible patients. Acta Anaesthesiol Belg 1990;41:87-94.
30. Figarella-Branger D, Kozak-Ribbens GK; Rodet L. Pathological findings in 165 patients explored for malignant hyperthermia susceptibility. Neuromuscul Disord 1993;3:553-556.
31. Harriman DGF. The pathology of malignant hypertermia. In: Mastaglia FL, Detchant LW (eds). Skeletal muscle pathology. 2Ed. Tokyo; Churchill Livingstone, 1992:541-562.
32. Silva HCA. Hipertermia maligna: positividade do teste de contratura muscular in vitro e alterações neuromusculares associadas. Tese Faculdade de Medicina da Universidade de São Paulo. São Paulo: 1999.
33. MacLennan DH. The role of skeletal muscle ryanodine receptor. Soc Gen Physiol Ser 1995;50:89-100.
34. Portel L, Hilbert G, Gruson D, Favier J-C. Gbikpi-Benissan G, Cardinaud J-P. Malignant hyperthermia and neuroleptic malignant syndrome in a patient during treatment for acute asthma. Acta Anaesthesiol Scand 1999;43:107-110.
35. Merry SN, Merry AF. Neuroleptic malignant syndrome and malignant hyperthermia.[Letter] N Z Med J 1988;101:431.